- Home
- AKBA vs XYF Comparison
AKBA vs XYF Comparison
Compare AKBA & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- XYF
- Stock Information
- Founded
- AKBA 2007
- XYF 2014
- Country
- AKBA United States
- XYF China
- Employees
- AKBA N/A
- XYF N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- XYF Finance: Consumer Services
- Sector
- AKBA Health Care
- XYF Finance
- Exchange
- AKBA Nasdaq
- XYF Nasdaq
- Market Cap
- AKBA 336.2M
- XYF 375.0M
- IPO Year
- AKBA 2014
- XYF 2018
- Fundamental
- Price
- AKBA $1.80
- XYF $10.59
- Analyst Decision
- AKBA Strong Buy
- XYF
- Analyst Count
- AKBA 1
- XYF 0
- Target Price
- AKBA $7.50
- XYF N/A
- AVG Volume (30 Days)
- AKBA 1.8M
- XYF 95.3K
- Earning Date
- AKBA 03-13-2025
- XYF 03-25-2025
- Dividend Yield
- AKBA N/A
- XYF 3.21%
- EPS Growth
- AKBA N/A
- XYF 2.79
- EPS
- AKBA N/A
- XYF 3.88
- Revenue
- AKBA $169,879,000.00
- XYF $763,521,851.00
- Revenue This Year
- AKBA N/A
- XYF N/A
- Revenue Next Year
- AKBA $19.31
- XYF N/A
- P/E Ratio
- AKBA N/A
- XYF $2.73
- Revenue Growth
- AKBA N/A
- XYF 16.99
- 52 Week Low
- AKBA $0.80
- XYF $3.48
- 52 Week High
- AKBA $2.48
- XYF $12.37
- Technical
- Relative Strength Index (RSI)
- AKBA 28.80
- XYF 73.95
- Support Level
- AKBA $2.07
- XYF $8.12
- Resistance Level
- AKBA $2.17
- XYF $12.37
- Average True Range (ATR)
- AKBA 0.08
- XYF 0.69
- MACD
- AKBA -0.05
- XYF 0.29
- Stochastic Oscillator
- AKBA 4.60
- XYF 61.07
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.